Binex cuts bio drug manufacturing supply contract value to 15.92 billion won

PUBT · 2d ago
Binex cuts bio drug manufacturing supply contract value to 15.92 billion won
  • Binex corrected a sales and supply contract for biopharmaceutical manufacturing, citing execution of an amended agreement.
  • Confirmed contract value cut to 15.92 billion from 17.44 billion; revenue impact revised to 10.28% from 11.27%.
  • Contract end date extended to Dec. 31, 2027 from Sept. 30, 2026; disclosure hold deadline moved to Dec. 31, 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Binex Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260930900875), on September 30, 2026, and is solely responsible for the information contained therein.